Animal Testing Ban – What’s next?

Workshop Date: 1 April 2014
Venue: Halls A1-A4, Hamburg Messe, Messeplatz 1, D-20357 Hamburg

SESSION 1 - MORNING / 9.00 – 12.30


09.00 - 09.15 Welcome, Introduction of the Agenda for the Day & the Session Speakers
Steven L. Hanft, CONUSBAT, Germany

09.15 - 09.45 Animal Testing for Cosmetics in a World-Wide Perspective
- Regulatory positions in major global economies
- Perception of the market participants, manufacturers and consumers
- Role of international organizations in the move towards alternatives: OECD, ICCVAM, etc.
- REACH and alternative testing methods
Speaker: Dr. Annelie Struessmann, CONUSBAT, Germany

09.45 - 10.30 The EU’s Animal Testing Ban
- Overview of the EU’s ban history
- 3R-approach – limitations for cosmetics
- The situation in Europe after the final implementation deadline in March 2013
- Method validation vs. regulatory acceptance
- Outlook on test validation timelines
Speaker: Dr. Patric Amcoff, Cosmetics Europe [CE], Belgium

10.45 - 12.30 Session Part 2: Existing In-Vitro, In-Silico and In-Chemico Alternatives, Pros/Cons - Significance vs. Animal Test End Point

10.45 - 11.30 Implementing Alternatives to Animal Testing
- OECD Test guidelines, including development of In-vitro, in-silico, in-chemico methods
- Techniques and methods for data gap filling - use of eChemPortal and QSAR Toolbox, etc.
- Development of Adverse Outcome Pathways and their regulatory applications
- Tools and Guidance: Status, documentation, access
Speaker: Dr. Joop de Knecht, Environment Directorate, OECD, Paris/F

11.30 - 12.00 Existing Alternative for Skin Irritation / Corrosion
- RHE - sources of cells, cultivation, difference to in-vivo cells, testing criteria
- Alternative tests - other advantages: Human cells vs. animal cells, more basic knowledge on pathways
- Experiences, acceptance
Speaker: Dr. Christian Pellevoisin, SkinEthic Academy, France

12.00 - 12.30 3D Tissues for Genotoxicity – A Validation Scenario
- Validation Process – who is involved, what are the steps
- Situation in mutagenicity testing – approached value of the new test
Speaker: Desmond (Des) Cave, BioReliance, UK

SESSION 2 - AFTERNOON / 13.30 - 17.30

13.30 - 15.00 Session Part 1: Biochemical Target Mechanisms and Alternative Testing Strategies
13.30 - 14.15 **Skin Toxicology: Biochemical Mechanisms and their Reflection in Toxicological Testing**
- Key considerations in skin safety assessment – the uniqueness of skin
- Testing methods - correlation to biochemical mechanisms and limitations
- The unexplained gap - type 1 immediate hypersensitization
- RIPT - an example for existing limitations in testing
- The functional proteomics premise - what can we borrow from pharmaceutics?
- Summary and future perspectives
  Speaker: **Dr. Nava Dayan**, **Dr. Nava Dayan LLC, USA**

14.15 - 15.00 **Skin Sensitization as Example of a Comprehensive Testing Strategy**
- Applying the OECD Adverse Outcome Pathway for the sensitization endpoint
- The mosaic pieces for sensitization assessment
- Interpretation – comparison to animal testing results
  Speaker: **Dr. Reinhard Kreiling**, **Clariant, Chair EFiCI Toxicology Working Group, Germany**

15.15 - 17.00 **Session Part 2: Consequences of the Animal Testing Ban for New Product Development**

15.15 - 16.00 **Animal Testing Ban / Marketing Ban - Consequences for Cosmetic Ingredients**
- Cosmetics ingredients – data required
- Animal Testing Ban / Marketing Ban (1223/2009)
- Avoiding animal testing
- Challenges for ingredients including innovations
  Speaker: **Ellen Pfrommer**, **BASF, Germany**

16.00 - 16.30 **Summary on Options, Restrictions & Legal Positions towards Alternative Approaches & Introduction to the Panel Discussion**

16.30 - 17.30 **Panel Discussion based on an Assessment Scenario under the Animal Testing Ban for a New Cosmetic Ingredient in Skin Whitening Products**
  Panel: **Dr. Patric Amcoff, Dr. Nava Dayan, Dr. Reinhard Kreiling, Ellen Pfrommer, Dr. Theresa Callaghan**

  * Callaghan Consulting International, Hamburg, Germany